ReAlta Life Sciences

Earlier today we announced the first patient dosed in our Phase 2 trial of RLS-0071 for the treatment of hospitalized patients with steroid-refractory Acute Graft-versus-Host Disease. Our novel, dual-targeting mechanism of action is well positioned to inhibit the neutrophil- and complement-driven inflammatory processes at work in aGvHD. #GvHD #inflammation #rarediseases https://lnkd.in/e9WPeCg5

ReAlta welcomes Peter Ho to our executive management team as Head of Business Development and Corporate Strategy, joining at this pivotal time in our development as we advance our three Phase 2 programs in rare and acute inflammatory diseases. https://lnkd.in/dJSAy85b #HIE #GvHD #COPD

Don't miss the recent Peer Review article in Endpoints News noting David Marek and Paolo Martini joining the ReAlta team as CEO and Chief Research & Development Officer, respectively. Also highlighted board members Christi Shaw and Emma Reeve. https://lnkd.in/eiWUe6BW #biotech #757proud #leadership

ReAlta is excited to announce the appointment of David Marek as Chief Executive Officer of ReAlta and Paolo Martini as Chief Research and Development Officer. Mr. Marek is a current ReAlta Board member and accomplished executive who, as CEO of Myovant Sciences, led the organization through the landmark sale of the company. Mr. Marek will lead ReAlta through potential regulatory approval and commercialization of the Company’s three Phase 2 clinical programs. Paolo Martini, Ph.D., joins ReAlta from Moderna, where he was Chief Scientific Officer and founder of Moderna Rare Diseases. At ReAlta, Dr. Martini will advance the Company’s pipeline of rare and acute inflammatory disease therapeutics. https://lnkd.in/ehZrUnak #rarediseases #clinicalresearch #HIE #GvHD #COPD

ReAlta is pleased to announce that FDA has granted Orphan Drug Designation and Fast Track Designation to our lead compound, RLS-0071, as a therapy for the treatment of patients with steroid-refractory acute graft-versus-host disease. This is our second indication to receive both designations, following previous designations for hypoxic ischemic encephalopathy (HIE). https://lnkd.in/dx2_34Wn #GVHD #clinicalresearch #rarediseases

ReAlta welcomes distinguished finance executive Emma Reeve to our board of directors. We are fortunate to have a strong, talented board filled with accomplished life sciences leaders like Emma guiding us in the next stage of our development! https://lnkd.in/eGVa8Ejz

ReAlta CEO Ulrich Thienel and CFO John Rickman are attending the Evercore ISI, Research Division 2024 Emerging Biotech Conference February 28-29th, where they are meeting with investors to discuss our EPICC platform and progress in the Phase 2 clinical trials underway for hypoxic-ischemic encephalopathy (HIE), acute exacerbations of COPD, and acute graft-versus-host disease (GvHD). As part of the conference, Dr. Thienel will be presenting an overview of the company's platform technology to investors at 2:15pm EST on Thursday, February 29th. #biotech #rarediseases #HIE #GvHD #COPD

We appreciate the strong support and encouragement from Norfolk Innovation Corridor for our work to address Acute Exacerbations of COPD and other rare and acute inflammatory diseases! #HIE #gvhd #copd #757proud

Thanks to our friends at Virginia Bio for posting about our update on the Acute COPD Exacerbations trial today! https://lnkd.in/eT3mffAN

ReAlta is proud to announce that we have successfully dosed our first patient in our Phase 2 trial of RLS-0071 for the treatment of acute exacerbations of COPD in hospitalized patients. With two Phase 2 trials now actively enrolling patients, ReAlta today's announcement is another important milestone as we explore the potential for RLS-0071 across multiple therapeutic areas. #COPD #clinicalresearch #HIE #GvHD #757proud https://lnkd.in/edTyScmr